1/2 /3-4/ 5-9/Aa-Am/An-Az/B/Ca-Ce/Cf-Cz/Da-Dh/Di-Dz/E/F/G/H/I/J/K/L/M/N/O/Pa-Pf/ /Pj-Po/Pp-Pz/Q/R/Sa-Ss/St-y/Ta-Th/Ti-Tz/U/V/W/X/Y/Z / Chinese spelling
|
|
 |
offer you
better services | ||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Docetaxel |
||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
DESCRIPTION Docetaxel is an antineoplastic agent belonging to the taxoid family. It is prepared by semisynthesis beginning with a precursor extracted from the renewable needle biomass of yew plants. The chemical name for docetaxel is (2R,3S)-N-carboxy-3-phenylisoserine, N-tert-butyl ester, 13-ester with 5b-20-epoxy-12a,4,7b,10b,13a-hexahydroxytax- 11-en-9-one 4-acetate 2-benzoate, trihydrate. Docetaxel is a white
to almost-white powder with an empirical formula of C43H53NO14?
3H2O, and a molecular weight of 861.9. It is highly lipophilic and
practically insoluble in water. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Applications | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| A
drug developed by Aventis Pharmaceuticals (formerly Rh?ne-Poulenc
Rorer Pharmaceuticals Inc. and Hoechst Marion Roussel, Inc.) for the
treatment of certain types of cancer,
Taxotere is now approved in 90 countries to treat advanced breast cancer and 70 countries to treat patients with advanced non-small-cell lung cancer. BREAST CANCER Taxotere is
the first anticancer agent to show a significantly higher response
rate than Adriamycin? (doxorubicin), a very active agent and widely
used chemotherapy in the first-line treatment of Taxotere as
a single agent was compared to mitomycin C in combination with vinblastine
and showed a one-year survival rate of 49 percent among breast cancer
patients, compared to 33 percent for those treated with the combination
therapy. Fifty percent more patients treated with Taxotere were
alive one year after therapy, compared to those treated with the
combination. Median time to progression and time to treatment failure
were significantly longer for Taxotere has been studied extensively in more than 200 clinical trials involving more than 85,000 patients worldwide. Approximately 10,000 breast cancer patients worldwide have been treated with Taxotere. In one randomized
Phase III multi-center study, Taxotere showed a 50 percent better
overall response rate compared to patients treated with Adriamycin
(45 percent for Taxotere vs. 30 percent for Adriamycin). The overall
response ate is the partial response rate (50 percent of greater
reduction in Patients in both Phase III trials were a poor prognostic group. In the study of Taxotere versus doxorubicin, three-quarters of all patients had disease that had spread to other internal organs, almost half had three or more organs showing evidence of disease and approximately half had received prior chemotherapy for metastatic disease. In the trial of Taxotere versus mitomycin C plus vinblastine, approximately half the patients had liver metastases, three-quarters had disease that had spread to other internal organs, and about one-third had received chemotherapy in both the adjuvant and metastatic setting. LUNG CANCER - Non-Small-Cell Lung Cancer Taxotere is the first chemotherapy agent shown to significantly improve survival for patients after failure of prior platinum-based chemotherapy. It is the first chemotherapy agent to be approved by the U.S. Food and Drug Administration for the second-line treatment of advanced NSCLC. In a Phase III clinical study involving NSCLC patients whose disease had progressed on prior platinum-based chemotherapy, patients treated with Taxotere 75 mg/m2 plus best supportive care had a significantly higher one-year survival rate (37 percent) compared to patients who received best supportive care alone (12 percent). In another study, NSCLC patients who had undergone prior platinum-based chemotherapy had a higher one-year survival rate when treated with Taxotere than with either Navelbine? (vinorelbine) or Ifex? (ifosfamide), two other chemotherapy agents. Of the patients treated with 75 mg/m2 of Taxotere, 30 percent were alive at one year, as compared to 20 percent of those treated with vinorelbine or ifosfamide. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Packing &loading | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
This data is only for your information purposes and does not imply
guarantee for a certain application. Please note: We do not deliver the product Docetaxole to private users! |
||||||||||||||||||||||||||||||||||||||||||||||||||||||
| If you need an indicative price to your country, please kindly advise the annual quantity needed, destination port and we will send you our soonest CNF(Cost + Freight) price. Your indication for a workable price level will sure speed up our fastest service for you | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
We really need to get
feed back from our customers in order to improve our performances. Best regards from SHENZHEN , China Mr. JEFFERY TSUI |
||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Material Safety Data Sheet | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Related Informations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacology of Paclitaxel and Docetaxel | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Description and Natural History of the English and Pacific Yews | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical Attributes of Taxus brevifolia - The Pacific Yew | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||
| If the above information doesn't cover | |
contact us
| ||||||||||||||||||||||||||||||||||||||||||||||||||||
